Omega-3 Fatty Acids and ASCVD

What’s the role of omega-3 fatty acids in treating patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD)?

What’s the role of omega-3 fatty acids in treating patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD)?

Enroll in this meeting
March 21, 2020
06:30 PM - 09:00 PM EDT
Gaylord National Resort & Convention Center
Ballroom: National Harbor 6 & 7, 201 Waterfront Street, National Harbor, Maryland, United States
Enrollment Fee: Free
Free
  • Overview

    During this interactive and engaging activity, we will focus on addressing the role of omega-3 fatty acids in treating patients with or at high risk of atherosclerotic cardiovascular disease (ASCVD) using the most recent evidence and guideline recommendations.

  • Program Schedule*

    6:30 pm–7:00 pm             

    Registration and Dinner

     

     

    7:00 pm–7:10 pm

    Welcome, Introductions, Program Overview
    Dave L. Dixon, PharmD - Chair

     

     

    7:10 pm–7:35 pm

    Clinical Trial Evidence of Omega-3 Fatty Acids in ASCVD
    Joseph Saseen, PharmD

     

     

    7:35 pm–8:00 pm

    Mechanisms and Comparisons of Omega-3s
    Daniel E. Hilleman, PharmD

     

     

    8:00 pm–8:25 pm

    Clinical Utility of Adjunct Therapies to Statins for ASCVD Event Reduction
    Dave L. Dixon, PharmD - Chair

     

     

    8:25 pm–8:40 pm

    Discussion, Questions and Answers
    All Faculty

     

     

    8:40 pm–8:55 pm

    Controversies in ASCVD
    All Faculty

     

     

    8:55 pm–9:00 pm

    Closing Comments, Adjourn
    Dave L. Dixon, PharmD - Chair

  • Learning Objectives

    At the conclusion of this activity, learners should be better able to:

    • Describe the spectrum of large-scale omega-3 fatty acids on ASCVD outcomes trials
    • Appreciate the difference between omega-3 fatty acids and their formulations to impact ASCVD events, including the negative role of dietary supplements
    • Use information on clinical utility of adjuncts to statin therapy to improve management of patients with or at high risk of ASCVD events
  • Target Audience

    This activity is designed to meet the educational needs of retail, hospital and managed care pharmacists.

  • Accreditation and Credit Designation Statements

    Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
    UAN: 0430-9999-20-002-L01-P
    Credits: 2.0  (0.20 CEU) for this CE activity
    Type of Activity: Application

    Estimated time to complete activity: 120 minutes

  • Commercial Support

    This activity is supported by an independent educational grant from Amarin Pharma, Inc.

  • ADA Statement

    Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Jessica McGrory prior to the live event at jmcgrory@omnia-prova.com.

Facebook Comments

Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free